Wells Fargo
LYEL icon

Wells Fargo’s Lyell Immunopharma LYEL Stock Holding History

Wells Fargo’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.51K Hold
125
– – ﹤0.01% 6224
2025
Q4 		$3.85K Buy
+125
New +$2.8K ﹤0.01% 6151
2025
Q3 		– Sell
-1,970
Closed -$17.4K – 7269
2025
Q2 		$17.4K Sell
1,970
-2,853
-59% -$26K ﹤0.01% 5823
2025
Q1 		$51.9K Buy
4,823
+107
+2% +$1.31K ﹤0.01% 5383
2024
Q4 		$60.4K Buy
4,716
+1,027
+28% +$20.4K ﹤0.01% 5416
2024
Q3 		$102K Buy
3,689
+159
+5% +$4.67K ﹤0.01% 5015
2024
Q2 		$102K Buy
3,530
+468
+15% +$22.3K ﹤0.01% 4929
2024
Q1 		$137K Buy
3,062
+393
+15% +$16.8K ﹤0.01% 4709
2023
Q4 		$104K Sell
2,669
-3,334
-56% -$120K ﹤0.01% 4877
2023
Q3 		$176K Sell
6,003
-33
-0.5% -$1.57K ﹤0.01% 4444
2023
Q2 		$384K Buy
6,036
+296
+5% +$16.4K ﹤0.01% 4136
2023
Q1 		$271K Buy
+5,740
New +$307K ﹤0.01% 4251
2022
Q4 		– Sell
-78
Closed -$12K – 7613
2022
Q3 		$12K Buy
78
+18
+30% +$2.44K ﹤0.01% 5612
2022
Q2 		$8K Sell
60
-394
-87% -$40.3K ﹤0.01% 5842
2022
Q1 		$46K Buy
454
+452
+22,600% +$54.8K ﹤0.01% 5698
2021
Q4 		$0 Sell
2
-4
-67% -$892 ﹤0.01% 7573
2021
Q3 		$2K Buy
+6
New +$1.8K ﹤0.01% 6578

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wells Fargo's LYEL Position: Q1 2026 in Review

Wells Fargo held its Lyell Immunopharma (LYEL) position steady in Q1 2026 at 125 shares worth $2.51K. The position accounts for ﹤0.01% of the portfolio, ranked #6224.

Wells Fargo first reported a position in LYEL in Q3 2021 and has held it in 17 quarters since. The position peaked at $384K in Q2 2023. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Wells Fargo held 125 shares of Lyell Immunopharma worth $2.51K as of Q1 2026.
  • Wells Fargo left its Lyell Immunopharma share count unchanged in Q1 2026.
  • Lyell Immunopharma made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6224 holding.
  • Wells Fargo first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 17 quarters since.
  • Wells Fargo's Lyell Immunopharma position peaked at $384K in Q2 2023.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.